Cargando…
De-escalated radiotherapy for HER2-overexpressing breast cancer patients with 1-3 positive lymph nodes undergoing anti-HER2 targeted therapy
BACKGROUND: In the era of anti-HER2 targeted therapy, the potential clinical feasibility of considering HER2-overexpressing breast cancer cases presenting with 1-3 positive axillary lymph nodes as low-risk, and thereby contemplating postoperative radiotherapy reduction, remains an important subject...
Autores principales: | Liu, Jing, Huang, Suning, Bi, Zhuofei, Zhang, Xiaoxue, He, Ziqing, Lan, Xiaowen, Tan, Yuting, Lin, Xiao, Zhou, Wenyi, Huang, Xiaobo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646411/ https://www.ncbi.nlm.nih.gov/pubmed/38023183 http://dx.doi.org/10.3389/fonc.2023.1280900 |
Ejemplares similares
-
Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
por: Tokuda, Y, et al.
Publicado: (1999) -
EGFR and HER2 expression in primary cervical cancers and corresponding lymph node metastases: Implications for targeted radiotherapy
por: Shen, Li, et al.
Publicado: (2008) -
EGFR, HER2, and HER3 protein expression in paired primary tumor and lymph node metastasis of colorectal cancer
por: Ye, Peng, et al.
Publicado: (2022) -
Overexpression of HER2/HER3 and clinical feature of ovarian cancer
por: Chung, Ye Won, et al.
Publicado: (2019) -
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
por: Horimoto, Yoshiya, et al.
Publicado: (2022)